Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

77.70CHF
23 Sep 2016
Change (% chg)

CHF1.45 (+1.90%)
Prev Close
CHF76.25
Open
CHF76.20
Day's High
CHF78.50
Day's Low
CHF75.70
Volume
85,912
Avg. Vol
54,728
52-wk High
CHF109.50
52-wk Low
CHF58.80

Latest Key Developments (Source: Significant Developments)

Basilea announces distribution agreement with Unimedic for Cresemba and Zevtera in Nordic Countries
Tuesday, 20 Sep 2016 01:15am EDT 

Basilea Pharmaceutica AG :Announces distribution agreement with unimedic for Cresemba (isavuconazole) and Zevtera (ceftobiprole) in Nordic Countries.  Full Article

Basilea announces partnership for antifungal isavuconazole in Japan
Thursday, 15 Sep 2016 01:15am EDT 

Basilea Pharmaceutica AG : Basilea announces partnership for antifungal isavuconazole in Japan with Asahi Kasei Pharma . Will receive an upfront payment of 7 million Swiss francs ($7.19 million) and will be eligible to receive up to approximately 60 million francs (at current exchange rate) of additional payments . Under terms of agreement, Asahi Kasei Pharma is granted an exclusive license to develop and commercialize isavuconazole in Japan .Basilea will also receive double-digit tiered royalties on product sales in Japan.  Full Article

Basilea: supply, distribution and license agreement with GBT
Tuesday, 13 Sep 2016 01:15am EDT 

Basilea Pharmaceutica AG : Basilea announces supply, distribution and license agreement with Grupo Biotoscana for CRESEMBA (isavuconazole) and Zevtera (ceftobiprole) in Latin America .In total, will receive upfront payments of 11 million Swiss francs ($11.32 million) for both drugs and will be eligible to receive payments upon achievement of regulatory and commercial milestones.  Full Article

Basilea Pharmaceutica: distribution agreement with Hikma for Cresemba in MENA region
Wednesday, 17 Aug 2016 01:15am EDT 

Basilea Pharmaceutica AG :Basilea announces distribution agreement with Hikma for Cresemba (isavuconazole) in the MENA region.  Full Article

Basilea Pharmaceutica H1 net loss narrows to CHF 27.9 million
Monday, 15 Aug 2016 01:15am EDT 

Basilea Pharmaceutica AG : Contract revenue in first half-year of 2016 amounted to 27.8 million Swiss francs ($28.50 million) (H1 2015: 24.4 million francs) . In H1 2016, operating loss amounted to 24.8 million francs, compared to 30.0 million francs in H1 2015 . H1 2016 product revenue amounted to 1.9 million francs (H1 2015: 0 million francs) . Total operating income in H1 2016 including sales amounted to 29.7 million francs (H1 2015: 25.0 million francs) . H1 net loss amounted to 27.9 million francs (H1 2015: 30.1 million francs) .Confirms guidance for total operating expenses for 2016 of approximately 9 - 10 million francs on average per month and average operating loss in 2016 of approximately 4 - 5 million francs per month.  Full Article

Basilea Pharmaceutica: CRESEMBA (isavuconazole) launched in Italy
Monday, 27 Jun 2016 01:15am EDT 

Basilea Pharmaceutica AG :Basilea's antifungal CRESEMBA (isavuconazole) launched in Italy.  Full Article

Basilea Pharmaceutica presents data on clinical oncology programs BAL101553 and BAL3833
Thursday, 21 Apr 2016 01:15am EDT 

Basilea Pharmaceutica AG:Reports presentation of data on clinical oncology programs BAL101553 and BAL3833 at AACR meeting.Tumor checkpoint controller BAL101553 demonstrates pre-clinical activity in treatment-refractory glioblastoma models as single agent and in combination treatment.PanRAF/SRC kinase inhibitor BAL3833 inhibits tumor growth in preclinical KRAS-driven cancer models.  Full Article

Basilea Pharmaceutica wins contract by BARDA of up to $100 mln funding for Ceftobiprole phase 3 program
Wednesday, 20 Apr 2016 01:15am EDT 

Basilea Pharmaceutica AG:Basilea awarded contract by BARDA of up to $100 million funding for Ceftobiprole phase 3 program.  Full Article

Basilea Pharmaceutica nominates Domenico Scala as new chairman of board​
Tuesday, 15 Mar 2016 02:15am EDT 

Basilea Pharmaceutica AG:Martin Nicklasson has determined not to stand for re-election as chairman but will stand for re-election as member of board.​Domenico Scala nominated as new chairman of board​.  Full Article

Basilea Pharmaceutica launches senior convertible bond issue, intends to withdraw U.S. IPO plans
Wednesday, 9 Dec 2015 01:15am EST 

Basilea Pharmaceutica AG:Launches a senior convertible bond issue.Launch of 175 million Swiss francs senior unsecured convertible bonds due 2022 with possibility of Basilea to increase by a maximum of 25 million francs to 200 million‍ francs.Bonds are expected to carry a coupon of between 2.75 pct and 3.50 pct per annum​ ‍.Payment and settlement of bonds is expected on or about Dec. 23.Intends to withdraw its previously announced F-1 public offering of common shares in U.S. in form of American depository shares following pricing of convertible bond.  Full Article

BRIEF-MedCap unit to distribute Basilea's products in Scandinavia

* Says its unit Unimedic Pharma AB has entered into licensing and distribution agreement with Basilea Pharmaceutica Ltd